title: LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.
abstract: We have reported that Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) can improve the chemosensitivity in U251 cells. However, the underlying mechanisms how LRIG1 improves the chemosensitivity remain unknown. In this study, we reported that LRIG1 can improve the chemosensitivity through the inhibition of B cell lymphoma 2 (BCL-2) and manganese superoxide dismutase (MnSOD). In addition, we showed that the expression level of LRIG1 was significantly negatively correlated with BCL-2 and MnSOD expression in glioma. Our research demonstrated that overexpression of LRIG1 can enhance the chemosensitivity. BCL-2 and MnSOD were inhibited in LRIG1 overexpressing cells. On the other hand, when BCL-2 and MnSOD were knocked down, the chemosensitivity of U251 cells decreased, and the effect of LRIG1 in regulating chemosensitivity was compromised. For the first time, our results showed that LRIG1 can enhance chemosensitivity in glioblastoma by inhibition of BCL-2 and MnSOD.
authors.affiliation: Zhongnan Hospital, Wuhan University, 125 Donghu Street, Wuhan, 430071, Hubei, China.
authors.forename: Jianjun
authors.initials: J
authors.lastname: Ding
authors.forename: Baohui
authors.initials: B
authors.lastname: Liu
authors.forename: Yi
authors.initials: Y
authors.lastname: He
authors.forename: Xianhou
authors.initials: X
authors.lastname: Yuan
authors.forename: Daofeng
authors.initials: D
authors.lastname: Tian
authors.forename: Baowei
authors.initials: B
authors.lastname: Ji
authors.forename: Long
authors.initials: L
authors.lastname: Wang
authors.forename: Liquan
authors.initials: L
authors.lastname: Wu
authors.forename: Huimin
authors.initials: H
authors.lastname: Dong
authors.forename: Junmin
authors.initials: J
authors.lastname: Wang
authors.forename: Xiaonan
authors.initials: X
authors.lastname: Zhu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Cai
authors.forename: Shenqi
authors.initials: S
authors.lastname: Zhang
authors.forename: Qianxue
authors.initials: Q
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D045744:Cell Line, Tumor; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D055785:Gene Knockdown Techniques; D005909:Glioblastoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008562:Membrane Glycoproteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics; D013482:Superoxide Dismutase / Q000037:antagonists & inhibitors* / Q000172:deficiency / Q000235:genetics; D000077204:Temozolomide; D055815:Young Adult; D000099156:Superoxide Dismutase 2
chemical_list: D003606:Dacarbazine; D008562:Membrane Glycoproteins; D019253:Proto-Oncogene Proteins c-bcl-2; D034741:RNA, Small Interfering; D013482:Superoxide Dismutase; D000077204:Temozolomide; D000099156:Superoxide Dismutase 2; C484445:LRIG1 protein, human